411 related articles for article (PubMed ID: 14701778)
1. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
Meyers CA; Smith JA; Bezjak A; Mehta MP; Liebmann J; Illidge T; Kunkler I; Caudrelier JM; Eisenberg PD; Meerwaldt J; Siemers R; Carrie C; Gaspar LE; Curran W; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2004 Jan; 22(1):157-65. PubMed ID: 14701778
[TBL] [Abstract][Full Text] [Related]
2. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
[TBL] [Abstract][Full Text] [Related]
3. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
4. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.
Mehta MP; Shapiro WR; Glantz MJ; Patchell RA; Weitzner MA; Meyers CA; Schultz CJ; Roa WH; Leibenhaut M; Ford J; Curran W; Phan S; Smith JA; Miller RA; Renschler MF
J Clin Oncol; 2002 Aug; 20(16):3445-53. PubMed ID: 12177105
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
Corn BW; Moughan J; Knisely JP; Fox SW; Chakravarti A; Yung WK; Curran WJ; Robins HI; Brachman DG; Henderson RH; Mehta MP; Movsas B
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):71-8. PubMed ID: 18164829
[TBL] [Abstract][Full Text] [Related]
6. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Chang EL; Wefel JS; Hess KR; Allen PK; Lang FF; Kornguth DG; Arbuckle RB; Swint JM; Shiu AS; Maor MH; Meyers CA
Lancet Oncol; 2009 Nov; 10(11):1037-44. PubMed ID: 19801201
[TBL] [Abstract][Full Text] [Related]
7. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function.
Li J; Bentzen SM; Renschler M; Mehta MP
J Clin Oncol; 2007 Apr; 25(10):1260-6. PubMed ID: 17401015
[TBL] [Abstract][Full Text] [Related]
8. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.
Li J; Bentzen SM; Li J; Renschler M; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):64-70. PubMed ID: 18406884
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.
McHaffie DR; Chabot P; Dagnault A; Suh JH; Fortin MA; Chang E; Timmerman R; Souhami L; Grecula J; Nabid A; Schultz C; Werner-Wasik M; Gaspar LE; Brachman D; Mody T; Mehta MP
J Neurooncol; 2011 Nov; 105(2):301-8. PubMed ID: 21523486
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
11. Motexafin gadolinium in the treatment of brain metastases.
Richards GM; Mehta MP
Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
13. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
Chabot P; Hsia TC; Ryu JS; Gorbunova V; Belda-Iniesta C; Ball D; Kio E; Mehta M; Papp K; Qin Q; Qian J; Holen KD; Giranda V; Suh JH
J Neurooncol; 2017 Jan; 131(1):105-115. PubMed ID: 27655223
[TBL] [Abstract][Full Text] [Related]
14. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.
Tsai PF; Yang CC; Chuang CC; Huang TY; Wu YM; Pai PC; Tseng CK; Wu TH; Shen YL; Lin SY
Radiat Oncol; 2015 Dec; 10():253. PubMed ID: 26654128
[TBL] [Abstract][Full Text] [Related]
15. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.
Postmus PE; Haaxma-Reiche H; Smit EF; Groen HJ; Karnicka H; Lewinski T; van Meerbeeck J; Clerico M; Gregor A; Curran D; Sahmoud T; Kirkpatrick A; Giaccone G
J Clin Oncol; 2000 Oct; 18(19):3400-8. PubMed ID: 11013281
[TBL] [Abstract][Full Text] [Related]
16. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
[TBL] [Abstract][Full Text] [Related]
17. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Evens AM
Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
[TBL] [Abstract][Full Text] [Related]
18. Strategies for preservation of memory function in patients with brain metastases.
Dye NB; Gondi V; Mehta MP
Chin Clin Oncol; 2015 Jun; 4(2):24. PubMed ID: 26112810
[TBL] [Abstract][Full Text] [Related]
19. Self-reported cognitive outcomes in patients with brain metastases before and after radiation therapy.
Cole AM; Scherwath A; Ernst G; Lanfermann H; Bremer M; Steinmann D
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):705-12. PubMed ID: 24064320
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: A preliminary report of a prospective phase II study.
Lin SY; Yang CC; Wu YM; Tseng CK; Wei KC; Chu YC; Hsieh HY; Wu TH; Pai PC; Hsu PW; Chuang CC
Biomed J; 2015; 38(5):439-49. PubMed ID: 25994802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
